Fig. 3 | Scientific Reports

Fig. 3

From: Glucagon-like peptide-1 receptor agonists improve metabolic dysfunction-associated steatotic liver disease outcomes

Fig. 3

Association of patients with MAFLD and GLP-1 agonists with cardiovascular and clinically significant portal hypertension events. p values were calculated from Kaplan-Meier survival curves and were conducted using the log-rank test. The data shows statistically significant improvement in portal hypertension events, composite cardiovascular events, and new-onset heart failure in the group treated with GLP-1 agonists at all time points analyzed.

Back to article page